Contributions of pharmaceutical interventions to the multidisciplinary dysphagia team: A retrospective observational study

Abstract Background The 2022 revision of Japanese healthcare reimbursement removed pharmacists from the mandatory dysphagia team, despite emerging evidence of medication-related swallowing complications. Our previous pharmacovigilance analysis identified dopamine-blocking drugs as primary contributo...

Full description

Saved in:
Bibliographic Details
Main Authors: Akihito Ueda, Michiko Obara, Shinichi Watanabe
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Journal of Pharmaceutical Health Care and Sciences
Subjects:
Online Access:https://doi.org/10.1186/s40780-025-00474-x
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849342124973096960
author Akihito Ueda
Michiko Obara
Shinichi Watanabe
author_facet Akihito Ueda
Michiko Obara
Shinichi Watanabe
author_sort Akihito Ueda
collection DOAJ
description Abstract Background The 2022 revision of Japanese healthcare reimbursement removed pharmacists from the mandatory dysphagia team, despite emerging evidence of medication-related swallowing complications. Our previous pharmacovigilance analysis identified dopamine-blocking drugs as primary contributors to the risk of aspiration pneumonia. This study aimed to validate these findings through a clinical examination of pharmaceutical interventions performed by a multidisciplinary dysphagia team. Methods This retrospective observational study was conducted at a 97-bed community hospital in Osaka, Japan, from June 2023 to January 2024. All adult patients with suspected dysphagia who underwent a multidisciplinary team intervention were included in our analysis. Pharmaceutical intervention was requested when medication-related dysphagia or swallowing difficulties were suspected, with interventions classified into the following four categories: drug-induced dysphagia management, dosage form optimization, swallowing aid utilization, and medication burden reduction. Changes in the medication burden were analyzed using paired t-tests. Results Among 59 patients with dysphagia (mean age, 81.1 ± 9.8 years; 33 males [55.9%], 26 females [44.1%]), 13 (22.0%) underwent pharmaceutical interventions. Drug-induced dysphagia management was the most common intervention (69.2%), targeting dopamine antagonists (sulpiride, risperidone, tiapride, and domperidone), benzodiazepines, and anticholinergics without dopamine-blocking effects. Suspected drug-induced dysphagia was the most common symptom among patients with dementia (38.9%). The intervention group showed a significant reduction in medication (mean, -3.2 medications; P < 0.001), whereas the non-intervention group showed no change. Among the non-intervention group, potential opportunities for the optimization of angiotensin-converting enzyme inhibitors were identified in antihypertensive therapy. Conclusions Pharmaceutical interventions may offer clinically meaningful contributions when utilized for patients with dysphagia, supporting the relevance of pharmacovigilance regarding the risks of dopamine antagonists. The findings of this study suggest the importance of reinstating pharmaceutical expertise to multidisciplinary dysphagia teams, as pharmacists provide clinically significant medication optimization, including identifying additional optimization opportunities through systematic medication reviews among vulnerable populations. 
format Article
id doaj-art-1e67643bddfe4723a7d57e9dab25352e
institution Kabale University
issn 2055-0294
language English
publishDate 2025-08-01
publisher BMC
record_format Article
series Journal of Pharmaceutical Health Care and Sciences
spelling doaj-art-1e67643bddfe4723a7d57e9dab25352e2025-08-20T03:43:29ZengBMCJournal of Pharmaceutical Health Care and Sciences2055-02942025-08-011111710.1186/s40780-025-00474-xContributions of pharmaceutical interventions to the multidisciplinary dysphagia team: A retrospective observational studyAkihito Ueda0Michiko Obara1Shinichi Watanabe2Doctoral Program in Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Teikyo Heisei UniversityFaculty of Pharmaceutical Sciences, Teikyo Heisei UniversityFaculty of Pharmaceutical Sciences, Teikyo Heisei UniversityAbstract Background The 2022 revision of Japanese healthcare reimbursement removed pharmacists from the mandatory dysphagia team, despite emerging evidence of medication-related swallowing complications. Our previous pharmacovigilance analysis identified dopamine-blocking drugs as primary contributors to the risk of aspiration pneumonia. This study aimed to validate these findings through a clinical examination of pharmaceutical interventions performed by a multidisciplinary dysphagia team. Methods This retrospective observational study was conducted at a 97-bed community hospital in Osaka, Japan, from June 2023 to January 2024. All adult patients with suspected dysphagia who underwent a multidisciplinary team intervention were included in our analysis. Pharmaceutical intervention was requested when medication-related dysphagia or swallowing difficulties were suspected, with interventions classified into the following four categories: drug-induced dysphagia management, dosage form optimization, swallowing aid utilization, and medication burden reduction. Changes in the medication burden were analyzed using paired t-tests. Results Among 59 patients with dysphagia (mean age, 81.1 ± 9.8 years; 33 males [55.9%], 26 females [44.1%]), 13 (22.0%) underwent pharmaceutical interventions. Drug-induced dysphagia management was the most common intervention (69.2%), targeting dopamine antagonists (sulpiride, risperidone, tiapride, and domperidone), benzodiazepines, and anticholinergics without dopamine-blocking effects. Suspected drug-induced dysphagia was the most common symptom among patients with dementia (38.9%). The intervention group showed a significant reduction in medication (mean, -3.2 medications; P < 0.001), whereas the non-intervention group showed no change. Among the non-intervention group, potential opportunities for the optimization of angiotensin-converting enzyme inhibitors were identified in antihypertensive therapy. Conclusions Pharmaceutical interventions may offer clinically meaningful contributions when utilized for patients with dysphagia, supporting the relevance of pharmacovigilance regarding the risks of dopamine antagonists. The findings of this study suggest the importance of reinstating pharmaceutical expertise to multidisciplinary dysphagia teams, as pharmacists provide clinically significant medication optimization, including identifying additional optimization opportunities through systematic medication reviews among vulnerable populations. https://doi.org/10.1186/s40780-025-00474-xDysphagiaDrug-induced dysphagiaPharmaceutical interventionMultidisciplinary teamDopamine antagonistPolypharmacy
spellingShingle Akihito Ueda
Michiko Obara
Shinichi Watanabe
Contributions of pharmaceutical interventions to the multidisciplinary dysphagia team: A retrospective observational study
Journal of Pharmaceutical Health Care and Sciences
Dysphagia
Drug-induced dysphagia
Pharmaceutical intervention
Multidisciplinary team
Dopamine antagonist
Polypharmacy
title Contributions of pharmaceutical interventions to the multidisciplinary dysphagia team: A retrospective observational study
title_full Contributions of pharmaceutical interventions to the multidisciplinary dysphagia team: A retrospective observational study
title_fullStr Contributions of pharmaceutical interventions to the multidisciplinary dysphagia team: A retrospective observational study
title_full_unstemmed Contributions of pharmaceutical interventions to the multidisciplinary dysphagia team: A retrospective observational study
title_short Contributions of pharmaceutical interventions to the multidisciplinary dysphagia team: A retrospective observational study
title_sort contributions of pharmaceutical interventions to the multidisciplinary dysphagia team a retrospective observational study
topic Dysphagia
Drug-induced dysphagia
Pharmaceutical intervention
Multidisciplinary team
Dopamine antagonist
Polypharmacy
url https://doi.org/10.1186/s40780-025-00474-x
work_keys_str_mv AT akihitoueda contributionsofpharmaceuticalinterventionstothemultidisciplinarydysphagiateamaretrospectiveobservationalstudy
AT michikoobara contributionsofpharmaceuticalinterventionstothemultidisciplinarydysphagiateamaretrospectiveobservationalstudy
AT shinichiwatanabe contributionsofpharmaceuticalinterventionstothemultidisciplinarydysphagiateamaretrospectiveobservationalstudy